Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin
The DOI matches its Crossref record.
Abstract
1. Elevation of blood pressure is one of the major side effects of recombinant human erythropoietin therapy in haemodialysis patients. 2. We investigated the possible involvement of endothelin in the pathogenesis of this recombinant human erythropoietin-induced blood pressure elevation in 51 patients undergoing maintenance haemodialysis. 3. Blood haemoglobin level increased from 7.1 ± 0.1 to 8.8 ± 0.1g/dl (means ± SEM) after 8 weeks of treatment with recombinant human erythropoietin (3000–4500 units/week). An increase in mean blood pressure was found in 19 patients (37%) (n = 9, by 0–10 mmHg; n = 10, by > 10 mmHg). 4. Plasma immunoreactive-endothelin concentration significantly increased from 2.26 ± 0.18 to 3.14 ± 0.31 pmol/l in the 10 patients whose mean blood pressure increased by more than 10 mmHg (P < 0.05), but not in the other patients. Moreover, the increase in plasma immunoreactive-endothelin concentration showed a significant positive correlation with the change in mean blood pressure in 19 patients with elevated mean blood pressure (r = 0.47, P < 0.05). 5. There was no significant correlation between the change in plasma immunoreactive-endothelin concentration and the change in blood haemoglobin level or the change in body weight. 6. These results suggest the possibility that endothelin may contribute to the recombinant human erythropoietin-related rise in blood pressure in some haemodialysis patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA)
Krapf, R., & Hulter, H. N. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05040908 · Cited by 180
Mechanism of erythropoietin-induced hypertension
Vaziri, N. D. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70413-0 · Cited by 154
Erythropoietin in the Treatment of Postural Orthostatic Tachycardia Syndrome
Kanjwal, K., Saeed, B., Karabin, B., Kanjwal, Y., Sheikh, M., & Grubb, B. P. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ef621a · Cited by 34
“erythropoietin, by elaborating hemoglobin, inhibits nitric oxide’s vasodilating effect and increases blood pressure.(18,19) In addition, erythropoietin increases tubular reabsorption of sodium,(20) and increases intracellular calcium in vascular smooth muscles thus increasing vascular resistance.”
Background
Metadata
- Authors
- Takahashi, K., Totsune, K., Imai, Y., Sone, M., Nozuki, M., Murakami, O., Sekino, H., & Mouri, T.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 1993-01-01
- Volume
- 84
- Issue
- 1
- Pages
- 47-50
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2419297389
- Cited by
- 52
- References
- 0
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. https://app.cochat.ai/papers/10.1042/cs0840047
- The paper
- Takahashi, K., Totsune, K., Imai, Y., Sone, M., Nozuki, M., Murakami, O., Sekino, H., & Mouri, T. (1993). Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clinical Science. https://doi.org/10.1042/cs0840047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.